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ASSOCIATION OF YOUNGER AGE WITH POOR GLYCAEMIC AND CHOLESTEROL
CONTROL IN ASIANS WITH TYPE-2 DIABETES IN SINGAPORE
Toh MPHS, Wu CX, Heng BH
National Healthcare Group, Singapore
OBJECTIVES: The National Healthcare Group Polyclinics (NHGP) is a group of 9
public sector primary care clinics in Singapore. This study examines the factors
associated with poor glycaemic control in Asian patients with type 2 diabetes mel-
litus (T2DM) in Singapore. METHODS: This is a cross-sectional study of patients
with T2DM who attended the same clinic in 2009 for the treatment of diabetes.
Demographic characteristics, medical diagnosis, clinical parameters and labora-
tory results were extracted from the group’s Diabetes Registry (CDMS). Glycaemic
(HbA1c) and cholesterol (LDL-c) control were compared with age and logistic re-
gression analysis was applied to study the factors associated with poor glycaemic
control usingHbA1c cut-off at 8%. RESULTS:Among the 58,057 T2DMpatientswere
more females (54%), disproportionately more Indians (13%) and fewer Chinese
(71%) than the general population. Both HbA1c and LDL-c improved with age. The
mean HbA1c decreased gradually from 8.161.74% (40 years) to 6.940.99% (80
years) while mean LDL-c dropped from 2.840.80 to 2.560.70. The Indian and
Malay groups had significantly poorer glycaemic control compared to the Chinese,
AdjOR 1.66 (95%CI:1.56-1.77) and 1.53 (95%CI:1.43-1.63) respectively. Other signifi-
cant predictors of poor glycaemic control included the male gender (AdjOR 1.19;
95%CI 1.19:1.14-1.25), presence of maculopathy or retinopathy, peripheral vascular
disease, coronary heart disease, heart failure, and being on insulin therapy (AdjOR
8.00; 95%CI:7.54-8.48). Patients with poor LDL-c (4.0 mmol/L) were 4.2 times the
odds of having poor glycaemic control (95%CI:3.78-4.66) while those with Grade 2
hypertension were 1.5 times (95%CI:1.35-1.76). CONCLUSIONS: Younger T2DM pa-
tients had poorer glycaemic and cholesterol control than older patients. Thosewith
poor glycaemic control also had corresponding poorer cholesterol and blood pres-
sure control. These patients had a higher lifetime risk of developing micro- and
macro-vascular complications and should be treated much more aggressively to
achieve “optimal” glycaemic and cholesterol control.
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FACTORS ASSOCIATED WITH ROUTINE PROPER MONITORING OF DIABETES
CARE AMONG THE NON-INSTITUTIONALIZED POPULATION IN THE UNITED
STATES: A RETROSPECTIVE ANALYSIS OF THE 2007 MEDICAL EXPENDITURE
PANEL SURVEY (MEPS)
Zhao Y, Fonseca V, Shi L
Tulane University, New Orleans, LA, USA
OBJECTIVES: This study aimed to examine the rate and predictors of diabetes
monitoring in the US. METHODS: This cross-sectional retrospective study was
conducted on a representative, non-institutionalized sample of the United States
population (the 2007 Household Component (HC) of the MEPS). According to the
American Diabetes Association (ADA) 2007 practice guidelines, proper provider
monitoring is defined as at least two A1c tests, one eye and one foot examination
annually. Health status was measured by SF-12. A logistic regression model was
used to examine the predictors of proper monitoring. Differences in health status
and medical expenditures between patients with and without proper monitoring
were examined using t-tests. Estimates were weighted to the total population
(WTP). RESULTS: Among 1,747 (WTP: 19,320,394) patients with diabetes, 80.64%
had at least two A1c tests; 63.29% had an eye examination; and 67.51% had a foot
examination. Thus, 63.36% patients (WTP: 14,065,289) received proper diabetes
monitoring. Older patients (OR:1.021, 95% confidence interval (CI):1.012-1.030),
non-Hispanic Caucasians compared with African Americans (OR:1.236, 95% CI:
0.933-1.636), patients with a higher education level (OR:1.211, 95% CI:1.056-1.390),
insurance coverage (OR:2.216, 95% CI:1.408-3.486), use of oral anti-diabetic drugs
(OR:2.935, 95% CI:2.131-4.042) and insulin (OR:3.453, 95% CI:2.477-4.814) were more
likely to undergo the proper monitoring. Well monitored patients had a higher
SF-12Mental Component Summary score (50.090.37 vs. 48.510.45, p0.05), but a
lower SF-12 Physical Component Summary score (39.950.34 vs. 42.280.47,
p0.05). Properly monitored patients spent significantly more on total health care
services ($5,243), outpatient visits ($1,023), and medications ($1,204), respec-
tively (all p-values0.05). CONCLUSIONS: In the United States, nearly 40% patients
with diabetes do not receive the proper diabetes monitoring according to the ADA
guidelines. In addition to racial and socioeconomic disparities, anti-diabetics/in-
sulin use,mental health status, physical health status, andhealth care expenditure
were associatedwith performingmonitoring. Cost-benefit of long-termmonitoring
should be studied.
Diabetes/Endocrine Disorders – Cost Studies
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ECONOMIC ASSESSMENT OF CONVERSION TO INSULIN PEN DEVICES IN A
LONG TERM CARE FACILITY CHAIN
Bazalo G1, Weiss RC2, Bouchard J3, Perry R4, Wendt F5
1Managed Solutions, LLC, Conifer, CO, USA, 2Managed Solutions, LLC, Randolph, NJ, USA, 3Novo
Nordisk, Inc., Princeton, NJ, USA, 4Senior PharmaStrategies, Hudson, FL, USA, 5Senior
PharmaStrategies, Burleson, TX, USA
OBJECTIVES: The objective of this study was to determine the economic impact of
a pharmacy program to convert insulin utilization from multi-dose vials to pen
delivery systems on a long termcare facility chain.METHODS: Purchasing datawas
obtained at the patient level for basal and short acting insulins from a chain of 75
skilled nursing facilities for the 12 month period ending June 2010. Data included
date dispensed, amount dispensed (mls), delivery system (pen or vial) and amount
paid to the dispensing pharmacy. The insulin cost per patient-day for each month
was calculated as total acquisition cost for the month divided by the number of
patient-days. The insulin cost per patient-day for each stay was calculated as the
total insulin acquisition cost divided by the length of stay in days. The mean cost
per patient-day for each patient stay subset based on payer type, length of stay and
delivery system used (pen only, vial only, pen and vial combination) was
calculated. RESULTS: There were 2,405 inpatient stays over the 12 month period,
70% covered by Medicare and 29% by Managed Care. Two-thirds of Medicare stays
and over three-fourths of managed care stays were 30 days or less. Pen device
purchases increased fromunder 1% to almost 35% of total purchases over the study
period duringwhich the insulin cost per day declined fromover $10 per patient-day
to $4. The cost per day for vial-only stays ($7.84) and combination vial and pen stays
($7.79) were 72% higher than pen-only stays ($4.54), despite a 39% price premium
per milliliter for pens. Differences were most marked for lengths of stay under 30
days.CONCLUSIONS:The increase in pen device usewas associatedwith amarked
decrease in insulin costs on a patient-day basis, particularly for lengths of stay
under 30 days.
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BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN IN THE
TREATMENT OF TYPE-2 DIABETES IN CHILE
Elgart J1, Caporale J2, Aiello EC3, Gagliardino JJ4, Waschbusch M3, Jotimliansky L3,
Valencia JE5
1National University of La Plata, La Plata, Buenos Aires, Argentina, 2Institute for Clinical
Effectiveness and Health Policy, Buenos Aires, Argentina, 3Bristol-Myers Squibb, Buenos Aires,
Argentina, 4CENEXA, La Plata, Buenos Aires, Argentina, 5Bristol-Myers Squibb, Bogota,
Colombia
OBJECTIVES: To estimate the budget impact of Saxagliptin introduction as a treat-
ment option for patients with type 2 diabetes mellitus (DM2) compared to the
present situation. METHODS: An MS Excel-based budget impact model assuming
coverage for onemillion people. The time horizonwas three years and the analysis
perspective was that of the public health care system in Chile. Pharmaceutical
expenses of antidiabetic agents were analyzed, excluding other medical costs. The
cost of antidiabetic agents was based upon list prices adjusted to co-payments,
expressed in 2009 US dollars; the Saxagliptin price was considered to be equal to
the sitagliptin price. The market share of the different drugs was based upon mar-
ket studies and data provided by Bristol Myers Squibb. The budget impact is re-
ported in terms of annual budget impact, per member per month (PMPM). The cost
of pioglitazone and rosiglitazone related cardiovascular events, as well as that of
sulphonylureas related hypoglycemia events were expressed as rates of occur-
rence per patient per year and cost per occurrence. RESULTS: The estimated net
budget impact for the introduction of Saxagliptin was US$ 70,723, US$ 162,885 and
US$ 251,574 for the first, second and third year respectively; the cumulative net
budget impact was US$ 485,181. PMPM was US$ 0.0059, US$ 0.0136 and US$ 0.0209
each year, respectively. The cumulative impact in the total annual budget for an-
tidiabetics represented an increase of 4.22%. CONCLUSIONS: The budget impact of
adding Saxagliptin in a population of one million people to the public health care
system in Chile is minimal in patients with DM2. The rise in pharmaceutical ex-
penses derived from introducing Saxagliptin into the formulary is balanced by
savings in terms of reduction of adverse events related to thiazolidinediones and
sulfonylureas, as well of lowering of insulin requirements in an extended time
horizon.
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A COST COMPARISON OF A BASAL BOLUS REGIMEN (INSULIN GLARGINE AND
INSULIN GLULISINE) WITH A CONVENTIONAL PRE-MIXED INSULIN REGIMEN IN
TYPE-2 DIABETES PATIENTS – THE GINGER STUDY
Tilling C1, Vora J2, Keech M3
1Sanofi-Aventis, Guildford, Surrey, UK, 2Royal Liverpool & Broadgreen University Hospitals,
Liverpool, UK, 3Pharmakos, St Albans, Hertfordshire, UK
OBJECTIVES: This cost analysis, based on the results of the GINGER study, aimed to
investigatewhether an intensified insulin regimen is better value than a 2 injection
per day conventional regimen. METHODS: GINGER was a 52 week multi-national
study in 310 T2D patients on insulin for an average of 5 years with poor glycaemic
control. It compared mealtime rapid-acting insulin glulisine (IGL) and insulin
glargine (IG) once daily with 2 injections per day of pre-mixed insulin. Use of IGL/IG
resulted in a change of HbA1C from baseline to endpoint of 1.31% and 0.80% for
pre-mixed insulin. Costs were calculated from a UK NHS perspective using MIMS
November 2010 prices. Insulin costs were based on the use of IGL/IG (Apidra Solo-
Star and Lantus SoloStar) and biphasic insulin aspart (BIA, NovoMix 30 FlexPen)
prefilled disposable injection devices. It was assumed that a newneedle, lancet and
blood glucose test strip were used for each injection with a 2U priming dose of
insulin before each injection. RESULTS: The annual drug cost per patient on IGL/IG
was higher than BIA at £692 and £612 respectively with the cost of metformin
similar for both groups. The cost of needles, lancets and test stripswasmuch lower
for BIA at £329 compared with £537 for the IGL/IG group. Overall the total annual
cost per patient for the IGL/IG group was £1243 compared with £957 for BIA. Over
the 52 weeks the relative cost of a 1% reduction in HbA1C was £949 for IGL/IG and
£1197 for BIA, a 1mmol/l reduction in FPG was £518 with IGL/IG and £563 with BIA.
Sensitivity analyses replacing BIA by insulin lispro or isophane insulin gave very
similar results. CONCLUSIONS: A similar reduction in HbA1C and FPG can be
achieved at a relatively lower cost with IGL/IG in comparison with BIA.
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INSULIN GLARGINE PLUS OHAS VERSUS BIPHASIC INSULIN IN TYPE-2
DIABETES – A COST COMPARISON
Tilling C1, Owens D2, Keech M3
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OBJECTIVES: As Type 2 Diabetes (T2D) progresses oral hypoglycaemic agents
(OHAs) alone fail tomaintain blood glucose control and insulin is required. LAPTOP
was a multi-national study comparing the addition of once daily insulin glargine
(IG, Lantus Solostar) to glimepiride and metformin with twice daily 30% regular/
70% human NPH insulin (Actraphane 30) without any additional OHAs in 371 T2D
patients over a 24 week period. IG plus OHAs was significantly more effective in
lowering HbA1C (1.64% vs1.31%). A cost minimisation analysis was undertaken
using LAPTOP data to compare the costs of the 2 regimens.METHODS:The analysis
was undertaken from a UK NHS perspective with prices from MIMS November
2010. Cost estimates were based on the use of non-proprietary OHAs and IG and
biphasic insulin aspart (BIA, NovoMix 30 FlexPen) prefilled disposable injection
devices. It was assumed anewneedle, lancet and blood glucose test stripwere used
for each injectionwith a 2Upriming dose of insulin before each injection.RESULTS:
Costs were calculated over the 24 week study period. The total cost of drugs per
patient on IG plus OHAs was slightly lower than BIA at £130 and £167 respectively
despite no OHA use in the BIA group (final mean insulin doses at 24 weeks IG 28.2U
and BIA 64.5U). The cost of needles, lancets and test strips was much lower for IG
plus OHAs at £76 comparedwith £152 for the BIA group. Overall the cost per patient
for 24 weeks for the IG plus OHAs group was £206 compared with £319 for BIA, a
difference of 35%. Sensitivity analyses replacing disposablewith reusable pens and
BIA by other biphasic insulins gave similar results to the base case. CONCLUSIONS:
In comparison with biphasic insulin the cost of IG plus OHAs was 35% less to
achieve an equivalent reduction in HbA1C.
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THE IMPACT OF TREATMENT MODIFICATION ON HEALTHCARE EXPENDITURE
IN PATIENTS WITH TYPE-2 DIABETES INITIATING EXENATIDE BID OR INSULIN
GLARGINE
Pawaskar M1, Bonafede M2, Johnson BH3, Fowler R3, Hoogwerf BJ1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Thomson Reuters, Cambridge, MA, USA,
3Thomson Reuters, Washington, DC, USA
OBJECTIVES: To examine the impact of treatment modifications on healthcare
expenditure for patients with type 2 diabetes (T2D) initiating exenatide BID (ex-
enatide) or insulin glargine. METHODS: A retrospective database analysis com-
prised of adult patients with T2D who initiated exenatide (N9197) or insulin
glargine (N4499) between 10/01/2006 and 03/31/2008 with 12 months pre- and 18
months post-index continuous enrollment. The 2 cohorts were 1:1 propensity
score matched on baseline demographics, clinical, and resource utilization vari-
ables. Treatment modification was defined as the first event intensification,
switching, or discontinuation of the index medication. The mean healthcare ex-
penditures in all patients and those experiencing treatment modifications were
estimated usingmultivariate regression. RESULTS: Baseline characteristics of pa-
tients on exenatide (n3774) and glargine (n3774) were well balanced after
matching with mean age of 57 years, mean Deyo Charlson Comorbidity score of
1.6, and proportionately more males (54%) in both cohorts. Glargine-treated
patients were 33%more likely to modify their treatment than exenatide-treated
patients (Hazard Ratio [HR]: 1.33, p0.0001). Compared to exenatide-treated
patients, glargine-treated patients were more likely to intensify (HR1.72,
p0.0001), or discontinue their treatment (HR1.25, p0.0001), but less likely to
switch to new therapy (HR0.71, p0.0001). Mean healthcare expenditure was
significantly lower for exenatide compared to glargine after 18 months (differ-
ence  $1667, p0.0001). Exenatide-treated patients who continued their treat-
ment had significantly lower expenditure of $1546 (p0.005) and those who
intensified their therapy also had significantly lower expenditure of $2472
(p0.001). There were no significant differences in expenditure for patients who
switched or discontinued their therapy. CONCLUSIONS: The likelihood of treat-
ment modification and mean total healthcare expenditure varied for patients ini-
tiating exenatide or glargine in real-world settings. Exenatide-treated patients had
lower mean healthcare expenditure compared to glargine-treated patients. Ex-
enatide-treated patients who continued or intensified their therapy also had asso-
ciated reduction in medical expenditure.
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DIRECT HEALTHCARE AND INDIRECT WORKLOSS COSTS ASSOCIATED WITH
THE ADDITION OF ROSIGLITAZONE (RSG) VERSUS SITAGLIPTIN (STG) THERAPY
TO METFORMIN (MET)
Lefebvre P1, Sarda SP2, Laliberté F1, Ramamurthy P2, Wei R2, Arondekar B3, Menditto L3,
Martin AA4, Duh MS2
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3GlaxoSmithKline, Philadelphia, PA, USA, 4GlaxoSmithKline, Uxbridge, UK
OBJECTIVES: We compared healthcare resource utilization (HRU) and costs asso-
ciated with add-on therapy of RSG versus STG to MET.METHODS: Type II diabetes
mellitus patients, 18 years, initiating RSG or STG (first dispensing  index date)
add-on therapy with MET were identified in the PharMetrics database (1999-2008).
Patients were continuously enrolled for 6 months pre-index (baseline) and 12
months post-index, had 1 dispensing for MET in the 6-month pre-index period,
did not use insulin or sulfonylurea, and were treated with RSGMET before 05/01/
2007 or STGMET for 6 months post-index. All-cause and diabetes-related HRU
and annual costs ($2008) were reported for the 12-month follow-up period. Work-
loss costs were estimated by applying hourly wage from the Bureau of Labor Sta-
tistics tomissedwork hours (hospitalization8 hours; outpatient/emergency room
[ER] visit4 hours). Multivariate analyses were conducted, adjusting for baseline
demographics, comorbidities, and costs. RESULTS: Compared to STGMET cohort
(N1,660) at baseline, RSGMET cohort (N3,731) was younger (55 vs. 58 years)
with fewer comorbidities (Charlson Comorbidity Index [0.26 vs. 0.34]), and had
lower total costs (RSGMET: $7,875; STGMET: $9,412; cost difference$1,536,
p0.0043). Frequency and costs of hospitalizations and ER visits were not different
at baseline. In the 12 months post-index period, all-cause HRU and corresponding
annual cost difference between RSGMET and STGMET cohorts was enlarged
(RSGMET: $8,443; STGMET: $10,757; cost difference$2,314, p0.0001). After ad-
justing for covariates, the cost decrease associated with RSGMET remained sta-
tistically significant (cost difference$1,248; cost ratio0.87; P0.0120). Diabetes-
related adjusted incremental cost saving of RSGMET over STGMET was $599
(cost ratio0.83, P0.0160). The adjusted workloss cost was also lower for
RSGMET compared to STGMET (cost difference$22, cost ratio0.93; P0.0120).
CONCLUSIONS: Compared to the newDPP-4 agent STG combinedwithMET, RSG, a
thiazolidinedione, combined with MET was associated with lower all-cause and
diabetes-related direct healthcare costs and indirect workloss costs.
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COST OF ALL-CAUSE AND CARDIOVASCULAR DISEASE-RELATED
HOSPITALIZATION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH
EXENATIDE BID, SULFONYLUREAS, OR INSULIN: A RETROSPECTIVE ANALYSIS
OF THE LIFELINK DATABASE
Best JH1, Pelletier E2, Smith DB2
1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health Incorporated, Watertown, MA,
USA
OBJECTIVES: To assess the cost of all-cause or cardiovascular disease-related
hospitalization in a real world setting among patients with type 2 diabetes
prescribed exenatide, a GLP-1 receptor agonist, compared to patients treated
with sulfonylureas or insulins. METHODS: Analyses included patients in the
LifeLink™ database initiating a new prescription for a glucose-lowering agent
between June 1, 2005 and March 31, 2009, without a prescription for the same
agent in the prior 9 months. Patients were followed for 12 months. Intention-
to-treat analyses of costs of all-cause and cardiovascular disease-related hos-
pitalization (myocardial infarction, stroke, or coronary revascularization), ad-
justed for differences in 300 clinical and demographic characteristics, were
compared using propensity-score-weighted methods. RESULTS: Mean age (SD)
was 53 (8) for patients treated with exenatide (n  14,400), 55 (12) for patients
treated with sulfonylureas (n  43,242), and 52 (12) for patients treated with
insulin (n  17,627); 43.4%, 53.5%, and 49.9% of patients treated with exenatide,
sulfonylureas, and insulin were male, respectively. More patients treated with
exenatide were obese (17.0%) than patients treated with sulfonylureas (7.4%) or
insulins (10.5%). Patients treated with exenatide were more likely to have hy-
perlipidemia (67.9%) than patients treated with sulfonylureas (49.9%) or insulins
(50.2%). Patients treated with exenatide had significantly lower mean (SD) all-
cause hospitalization costs than patients treated with sulfonylureas ($2,725 
16,463 Exenatide; $3,304  17,378 sulfonylureas; p 0.001) or insulin ($3,211 
17,969 Exenatide; $4,849  21,110 insulin; p 0.001). Patients treated with ex-
enatide also had significantly lower mean (SD) cardiovascular disease-related
hospitalization costs than patients treated with sulfonylureas ($428  6,174
Exenatide; $566  6,047 sulfonylureas; p 0.05) or insulin ($470  6,841 Ex-
enatide; $726  7,012, insulin; p 0.001). CONCLUSIONS: Exenatide treatment
was associated with significantly lower costs for all-cause and cardiovascular
disease-related hospitalization compared to treatment with sulfonylureas or
insulin.
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ECONOMIC EVALUATION OF GLIMEPIRIDE AND GLIMEPIRIDE/METFORMIN FOR
TYPE-2 DIABETES MELLITUS IN MEXICO
Carlos F1, Lemus A2
1R A C Salud Consultores S.A. de C.V., Mexico City, Mexico, 2Sanofi-Aventis, Mexico City, Mexico
OBJECTIVES: To perform an economic evaluation of the use of gliperimide (GMP)
and the fixed-dose combination (FDC) of glimepiride/metformin (GMP/Met) in the
treatment of patients with DM-2, from the Mexican Public Health System
perspective.METHODS: TwoMarkovmodels were designed for reflecting different
treatment sequences.Model 1 is for not controlled diet and exercise andmetformin
intolerant patients, where GMP is compared to glibenclamide (GBC) and thiazoli-
dinedione (TZD). Model 2 is for patients which the lifestyle changed and themono-
therapy with metformin was insufficient for reaching a level of HbA1c7%, and a
sulfonylurea/Met FDC is compared to TZD/Met. The direct costs of the drug treat-
ment and the hypoglycemia episode were calculated. The dosage and efficacy of
the oral antidiabetic agents and insulin were established based on the literature
review and local practice. The unit costs were elicited from official sources. The
time horizon was three years, divided in quarterly cycles. RESULTS: Therapy with
GMP was dominant versus the treatment sequences which included a beginning
therapy with thiazolidinedione. The savings after three years with GMP or GMP/
Met instead of using TZD ranged from US$288.7 to US$632.1 per patient. Although
GBC has a low cost, it is associated with an increase in the mortality rate and
hypoglycemia events. A FDC of GMP/Met caused an incremental cost of 20% versus
GBC andmetformin separately. The average costs per additional life year obtain by
using GMP instead of GBC ranged from US$3,074.9 to US$3,261.4. The probabilistic
sensibility analysis shows that GMP and GMP/Met resulted as highly cost-effective
in approximately 90% of the simulations. CONCLUSIONS: Glimepiride mono-
therapy (model 1) and the administration of GMP/Met (model 2) represent highly
cost-effective health interventions regarding the use of glibencamide and it is dom-
inant versus the use of thiazolidinedione.
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